Physician

Anna K Imperato, M.D.

According to 2025 Medicare claims, Anna Imperato, M.D. (NPI: 1104880780) practices rheumatology in the Nassau County-Suffolk County, NY market, with the plurality of this provider's patient population coming from Nassau, NY. This provider's primary affiliated billing organization is ANNA K IMPERATO MD PLLC (NPI: 1417272485; TIN: 800371564) and primary practice location at 11030-1977. Imperato is affiliated with the MaineHealth Accountable Care Organization (ACO ID: A1290), participating under the MSSP model.

Imperato's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 807 traditional Medicare patients, billed 133,780 HCPCS/CPT codes, and received $1,918,376 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,172 prescription claims across 393 beneficiaries totaling $4,952,701 in drug costs, led by Otezla (Apremilast). Open Payments data shows 300 records totaling $59,896. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $297,353 and ending at $1,918,376. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,959,732 to $4,952,701. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	505	15,125	$297,353
2016	547	15,235	$315,022
2017	606	31,447	$1,098,846
2018	590	58,594	$2,154,358
2019	635	73,865	$2,276,798
2020	623	84,629	$1,736,599
2021	839	105,372	$1,773,591
2022	718	96,859	$1,350,307
2023	755	105,570	$1,410,543
2024	807	133,780	$1,918,376

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	335	2,347	$1,959,732
2016	349	2,246	$1,935,902
2017	352	2,566	$2,417,224
2018	349	2,354	$3,581,570
2019	386	2,259	$3,705,699
2020	378	2,230	$4,234,181
2021	345	1,969	$3,875,805
2022	393	2,346	$5,776,861
2023	417	2,393	$6,095,178
2024	393	2,172	$4,952,701

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	176	183	$159
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	433	784	$112
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	352	801	$80
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	164	615	$72
36415	Insertion of needle into vein for collection of blood sample	196	250	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Otezla	Apremilast	106	4,380	$697,684
Arcalyst	Rilonacept	18	602	$475,084
Tremfya	Guselkumab	28	1,698	$431,617
Taltz Autoinjector	Ixekizumab	19	1,568	$372,406
Cosentyx Sensoready (2 Pens)	Secukinumab	39	1,316	$363,588

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	300	$59,896	Kiniksa Pharmaceuticals International, plc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anna K. Imperato, M.D.?

Tedicare shows public-source Medicare data for Anna K. Imperato, M.D. (NPI 1104880780), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anna K. Imperato, M.D. have ACO affiliation data?

Anna K. Imperato, M.D. is shown with ACO affiliation data for MaineHealth Accountable Care Organization (MSSP, ACO ID A1290).

What billing organization is linked to Anna K. Imperato, M.D.?

Anna K. Imperato, M.D. is linked to ANNA K IMPERATO MD PLLC (billing NPI 1417272485) in the available physician profile data.

Does Anna K. Imperato, M.D. have Open Payments data?

Anna K. Imperato, M.D. has 300 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.